A NSQIP-based randomized clinical trial evaluating choice of prophylactic antibiotics for pancreaticoduodenectomy Journal Article
| Authors: | Brajcich, B. C.; Ko, C. Y.; Liu, J. B.; Ellis, R. J.; D’Angelica, M. I. |
| Article Title: | A NSQIP-based randomized clinical trial evaluating choice of prophylactic antibiotics for pancreaticoduodenectomy |
| Abstract: | Surgical site infection is a common complication following pancreaticoduodenectomy and is a major source of postoperative morbidity. Surgical site infection is more common among patients who undergo preoperative biliary instrumentation, likely because of the introduction of intestinal flora into the normally sterile biliary tree. Frequently, bacterial isolates from surgical site infections after pancreaticoduodenectomy demonstrate resistance to the antibiotic agents typically used for surgical prophylaxis, suggesting that broad-spectrum coverage may be beneficial. This chapter summarizes the current evidence regarding surgical site infection following pancreatic surgery and describes the rationale and methodology underlying a multicenter randomized trial evaluating piperacillin-tazobactam compared with cefoxitin for surgical site infection prevention following pancreaticoduodenectomy. As the first U.S. randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials. The trial has successfully completed patient accrual, and study results are forthcoming. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2024. |
| Keywords: | controlled study; treatment outcome; antibiotic agent; clinical trial; nonhuman; treatment planning; pancreaticoduodenectomy; randomized controlled trial; morbidity; clinical protocol; history; antiinfective agent; anti-bacterial agents; register; multicenter study; clinical evaluation; surgical infection; surgical mortality; biliary tract drainage; risk reduction; antibiotic prophylaxis; cost benefit analysis; prevention and control; piperacillin plus tazobactam; data collection method; etiology; randomized controlled trial (topic); surgical wound infection; adverse event; cefazolin; procedures; piperacillin; cefmetazole; humans; human; cefoxitin; tigecycline; mortality risk; tazobactam drug combination; piperacillin, tazobactam drug combination; cefoperazone plus sulbactam |
| Journal Title: | Cancer Treatment and Research |
| Volume: | 192 |
| ISSN: | 0927-3042 |
| Publisher: | Springer |
| Date Published: | 2024-01-01 |
| Start Page: | 131 |
| End Page: | 145 |
| Language: | English |
| DOI: | 10.1007/978-3-031-61238-1_7 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Chapter 7 in "Gastrointestinal Malignancies. 2nd ed" (ISBN: 978-3-031-61237-4) -- Source: Scopus |
